NCT06190184

Brief Summary

US residents who have obesity and sign the informed consent form and are screened and enrolled for this study. Participants who are enrolled complete a survey upon enrollment and are randomized into one of two arms. This study is direct to participant and will not utilize clinical sites.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Oct 2023

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 26, 2023

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

December 8, 2023

Completed
28 days until next milestone

First Posted

Study publicly available on registry

January 5, 2024

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 31, 2024

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2024

Completed
Last Updated

January 5, 2024

Status Verified

January 1, 2024

Enrollment Period

1 year

First QC Date

December 8, 2023

Last Update Submit

January 3, 2024

Conditions

Keywords

Mental Healthdietsupplementsvitaminsstress

Outcome Measures

Primary Outcomes (4)

  • Change in PHQ-9 Score

    Change in PHQ-9 score for VPNP group compared to baseline scores.

    4 months

  • Change in GAD-7 Score

    Change in GAD-7 score for VPNP group compared to baseline scores.

    4 months

  • Change in Quality of Life Score

    Change in quality of life score for VPNP group compared to baseline scores.

    4 months

  • Change in Perceived Stress Scale Score

    Change in perceived stress score for VPNP group compared to baseline scores.

    4 months

Study Arms (2)

Placebo

PLACEBO COMPARATOR

Participants who have mental health issues are randomized into this study arm. They may be provided with any combination of nutritional recommendations and supplements. Placebo capsules will contain inert and inactive materials. Participants may need to use a mobile app in order to participate in the trial.

Other: Control arm

Viome's Precision Nutrition Program (VPNP)

EXPERIMENTAL

Participants who have mental health issues are randomized into this study arm. They may be provided with any combination of nutritional recommendations and supplements. Participants may need to use a mobile app in order to participate in the trial.

Combination Product: VIOME Precision Nutrition Program

Interventions

Precision supplement based on the participants microbiome sample results. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.

Also known as: VPNP
Viome's Precision Nutrition Program (VPNP)

Participants who have mental health issues are randomized into this arm. They may be provided with any combination of nutritional recommendations and/or supplements. Placebo capsules will contain inert and inactive materials. Participants may need to use a mobile app in order to participate in the trial.

Also known as: Placebo
Placebo

Eligibility Criteria

Age25 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Resident of the United States
  • years old and older OR BMI of 25 or greater
  • Able to speak and read English
  • No unexplained weight loss, fevers, anemia, or blood in stool
  • Willing and able to follow the trial instructions, as described in the recruitment letter
  • Signed and dated informed consent prior to any trial-specific procedures.
  • PHQ9 score of 5-24 (inclusive)

You may not qualify if:

  • Unwilling to change their current diet
  • Prior use of Viome products or services
  • Antibiotic use in the previous 4 weeks
  • Pregnancy (current or planned in the next 4 months)
  • \< 90 days postpartum
  • Breast feeding
  • Active infection
  • Unable or unwilling to use Viome's App on an iPhone or Android smartphone
  • Significant diet or lifestyle change in the previous 1 month
  • IBD diagnosis -Major psychiatric/DSM-4 disease diagnosis (e.g. Schizophrenia, Bipolar disorder, Post- traumatic Stress Disorder, Obsessive Compulsive disorder)
  • Use of investigational drugs, products or devices within 1 month prior to and 4 months after the start of the trial
  • Cancer therapy within the previous 1 year
  • Major surgery in the last 6 months or planned in the next 4 months
  • Allergies to any supplement ingredients listed in the screening survey
  • Currently on a specific diet: FODMAP, KETO, PALEO
  • +9 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Viome Life Sciences

Bothell, Washington, 98011, United States

RECRUITING

MeSH Terms

Conditions

Mental DisordersPsychological Well-BeingDepressionAnxiety Disorders

Condition Hierarchy (Ancestors)

Personal SatisfactionBehaviorBehavioral Symptoms

Study Officials

  • Momchilo Vuyisich

    Viome

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Momchilo Vuyisich

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Masking Details
Once enrolled, participants are randomized into one of the 2 study arms. The coded supplements with blinded labels are shipped to the participants. The participants are not aware of which group they are randomized into.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Randomized, blinded, cohort study divided into two study arms: 1) control group (placebo), 2) precision-supplement
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 8, 2023

First Posted

January 5, 2024

Study Start

October 26, 2023

Primary Completion

October 31, 2024

Study Completion

December 31, 2024

Last Updated

January 5, 2024

Record last verified: 2024-01

Locations